Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Phase 3

Completed

Conditions: Generalized Pustular Psoriasis

Interventions: Drug: spesolimab

First Posted Date: 2022-01-20

Last Posted Date: 2024-08-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 11

Registration Number: NCT05200247

Locations: 🇯🇵
Tokyo Medical University Hospital, Tokyo, Shinjuku-ku, Japan
🇯🇵
Tohoku University Hospital, Miyagi, Sendai, Japan
🇯🇵
Jichi Medical University Hospital, Tochigi, Shimotsuke, Japan

and more 6 locations

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 706321
Drug: Placebo

First Posted Date: 2022-01-10

Last Posted Date: 2024-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT05183360

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1291583
Drug: Placebo

First Posted Date: 2022-01-10

Last Posted Date: 2022-08-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT05183347

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Phase 2

Completed

Conditions: Kidney Disease, Chronic

Interventions: Drug: Placebo to BI 690517
Drug: Empagliflozin
Drug: BI 690517
Drug: Placebo to empagliflozin

First Posted Date: 2022-01-10

Last Posted Date: 2024-10-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 714

Registration Number: NCT05182840

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
PrimeCare Medical Group, Houston, Texas, United States

and more 199 locations

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: Stiolto Respimat
Device: Trelegy Ellipta
Drug: Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Drug: Tiotropium + Olodaterol (5/5 mcg)

First Posted Date: 2021-12-27

Last Posted Date: 2023-10-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9117

Registration Number: NCT05169424

Locations: 🇺🇸
eMax health, White Plains, New York, United States

To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
Drug: empagliflozin

First Posted Date: 2021-12-17

Last Posted Date: 2024-05-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 494679

Registration Number: NCT05162014

Locations: 🇩🇪
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live

Phase 2

Terminated

Conditions: Hypertension, Portal

Interventions: Drug: Avenciguat (BI 685509)
Drug: Placebo matching Avenciguat (BI 685509)

First Posted Date: 2021-12-17

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT05161481

Locations: 🇩🇰
Hvidovre Hospital, Hvidovre, Denmark
🇫🇷
HOP d'Angers, Angers, France
🇫🇷
HOP Rangueil, Toulouse, France

and more 42 locations

A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1358894, intended Commercial Formulation (iCF) (T)
Drug: BI 1358894, Trial Formulation 2 (TFII) (R)

First Posted Date: 2021-12-13

Last Posted Date: 2022-05-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT05155306

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: BI 1831169
Drug: anti-PD-1 antibody

First Posted Date: 2021-12-13

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 190

Registration Number: NCT05155332

Locations: 🇮🇹
ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
University of California Irvine, Orange, California, United States

and more 24 locations

A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 765250
Drug: Placebo

First Posted Date: 2021-12-09

Last Posted Date: 2024-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 135

Registration Number: NCT05151653

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy